|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | A61K 31/4709 | (2006.01) |
| A61K 31/00 | (2006.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 35/04 | (2006.01) | ||
| C12Q 1/68 | (2018.01) | ||
| C12Q 1/6886 | (2018.01) |
| (11) | Number of the document | 3534885 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17842428.9 |
| Date of filing the European patent application | 2017-11-02 | |
| (97) | Date of publication of the European application | 2019-09-11 |
| (45) | Date of publication and mention of the grant of the patent | 2021-01-20 |
| (46) | Date of publication of the claims translation | 2021-07-12 |
| (86) | Number | PCT/US2017/059686 |
| Date | 2017-11-02 |
| (87) | Number | WO 2018/085518 |
| Date | 2018-05-11 |
| (30) | Number | Date | Country code |
| 201662417044 P | 2016-11-03 | US |
| (72) |
GUALBERTO, Antonio, US
SCHOLZ, Catherine Rose, US
|
| (73) |
Kura Oncology, Inc.,
12730 High Bluff Drive, Suite 400, San Diego, CA 92130,
US
|
| (74) |
Aušra PAKĖNIENĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui |
| FARNESYLTRANSFERASE INHIBITORS FOR USE IN TREATING CANCER |
| Payment date | Validity (years) | Amount | |
| 2022-10-27 | 6 | 139.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2023-11-02 |